Hyaluronic Acid and Eye Health: Supporting Ocular Hydration

Hyaluronic Acid in Ocular Anatomy

Hyaluronic acid (HA) is deeply integrated into the anatomy and physiology of the human eye. It was, in fact, first isolated from the vitreous humor of the bovine eye in 1934. In the human eye, the vitreous humor—the clear, gel-like substance that fills the space between the lens and the retina—relies heavily on HA to maintain its structural integrity and clarity.

At the ocular surface, HA plays a pivotal role in the tear film. The tear film must remain stable to protect the cornea, ensure clear vision, and prevent desiccation. HA's immense water-binding capacity makes it an ideal molecule for maintaining this hydration barrier.

Tear Film Stability and Dry Eye Disease

Dry Eye Disease (DED) is a prevalent condition characterized by a loss of homeostasis of the tear film, leading to hyperosmolarity, ocular surface inflammation, and damage. HA exhibits high pseudo-plasticity, meaning its viscosity changes depending on applied shear forces. During a blink, the viscosity of an HA-containing tear film decreases, allowing for an even, frictionless distribution across the eye. Once at rest, higher viscosity is restored, which thickens and stabilizes the tear film, prolonging its residence time on the ocular surface (Acta Ophthalmologica).

This unique rheological property reduces evaporation from the ocular surface—a primary driver of the hyperosmolarity and inflammation seen in DED (Acta Ophthalmologica). Consequently, artificial tears containing HA (typically in concentrations ranging from 0.1% to 0.4%) are a frontline therapy, proven effective at improving both the signs and symptoms of DED (PubMed).

The Emerging Role of Oral Supplementation

While topical HA eye drops are the standard of care, emerging clinical evidence suggests that oral HA supplementation can provide complementary benefits for ocular health. A study evaluating the clinical efficacy of oral HA in patients with DED found that oral supplementation (240 mg daily) significantly improved tear break-up time (TBUT) and corneal surface health within one to three months (Journal of Ophthalmology).

The study concluded that a combined approach of both oral and topical HA more efficiently improves corneal epithelial wound healing and related dry eye symptoms than topical HA alone (Journal of Ophthalmology). This systemic distribution underscores the profound bioavailability of high-quality oral HA formulations.

Key Takeaways

• Structural Component: HA is a primary component of the eye's vitreous humor and is essential for maintaining ocular shape and clarity.
• Tear Film Stabilization: Its unique viscosity allows HA to spread evenly during blinking and thicken at rest, locking in moisture and preventing tear evaporation.
• Comprehensive Relief: Clinical evidence shows that combining oral HA supplementation with topical drops provides superior relief for dry eye symptoms compared to drops alone.